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Translational Relevance
The p53 tumor suppressor protein and its endogenous regulator MDM2 have been a focus of cancer research
for over 30 years, with several small molecule inhibitors of MDM2 evaluated in clinical trials. However, no
inhibitors of MDMX, the second regulator of p53, have been tested clinically, due in part to the challenge of
developing small molecule inhibitors of the p53-MDMX interface. Stapled Peptides are a new therapeutic
modality capable of disrupting protein-protein interactions in cells. ALRN-6924, a dual MDM2/MDMX
inhibitor, is the first member of this new modality to reach the clinic. We evaluated the safety,
pharmacokinetics, pharmacodynamics, and anti-tumor effects of ALRN-6924 in patients with solid tumors or
lymphomas, and show that ALRN-6924 was well tolerated with encouraging anti-tumor activity, including
durable complete and partial responses with more than half of evaluable patients achieving disease control.
Strikingly, the hematopoietic toxicity typically observed for selective MDM2 inhibitors was nearly absent
for ALRN-6924, suggesting that dual MDM2/MDMX inhibition may allow for more complete p53
activation with a toxicity profile that would allow for combination therapy and use as a chemoprotection
agent.
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PURPOSE
We describe the first-in-human dose-escalation trial for ALRN-6924, a stabilized, cell-permeating peptide that
disrupts p53 inhibition by MDM2 and MDMX to induce cell cycle arrest or apoptosis in TP53 wild-type
tumors.

METHODS
Two schedules were evaluated for safety, pharmacokinetics, pharmacodynamics, and anti-tumor effects in
patients with solid tumors or lymphomas: In arm A, patients received ALRN-6924 by intravenous infusion
once-weekly for 3 weeks every 28 days; arm B, was twice-weekly for 2 weeks every 21 days.

RESULTS
Seventy-one patients were enrolled: 41 in arm A (0.16-4.4 mg/kg), 30 in arm B (0.32-2.7 mg/kg). ALRN6924 showed dose-dependent pharmacokinetics and increased serum levels of MIC-1, a biomarker of p53
activation. The most frequent treatment-related adverse events were gastrointestinal side effects, fatigue,
anemia, and headache. In arm A, at 4.4 mg/kg, dose-limiting toxicities (DLTs) were Grade 3 (G3)
hypotension, G3 alkaline phosphatase elevation, G3 anemia, and G4 neutropenia in one patient each. At the
maximum tolerated dose in arm A of 3.1 mg/kg, G3 fatigue was observed in one patient. No DLTs were
observed in arm B. No G3/G4 thrombocytopenia was observed in any patient. Seven patients had infusionrelated reactions; three discontinued treatment. In 41 efficacy-evaluable patients with TP53 wild-type disease
across both schedules the disease control rate was 59%. Two patients had confirmed complete responses, two
had confirmed partial responses, 20 had stable disease. Six patients were treated for >1 year. The
recommended phase 2 dose was schedule A, 3.1 mg/kg.
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CONCLUSION
ALRN-6924 was well tolerated and demonstrated anti-tumor activity.
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Introduction
Commonly referred to as “the guardian of the genome,” p53 plays a central role in the mechanisms that
defend the human body from cancer.1 The natural tumor suppressor function of p53 involves responding to
DNA damage by arresting cell division, allowing for repair, and if repair is unsuccessful, inducing an
apoptotic response. To subvert this anti-tumor functionality, cancer cells neutralize p53 by deletion,
mutation, degradation, or sequestration.2,3 The latter two mechanisms are mediated by protein-protein
interactions between p53 and its negative regulators mouse double minute 2 (MDM2), which binds and
destroys p53; and MDMX, which binds and sequesters p53.4,5 Mutation of the TP53 gene that encodes the
p53 tumor suppressor protein has been observed in approximately 50% of adult and 4% of childhood
cancers, highlighting the importance of p53 signaling.6 Conversely, many human cancers retain wild-type
TP53, making reactivation of the natural p53 pathway by targeted inhibition of MDM2 and MDMX in TP53
wild-type cancer cells an appealing strategy for therapeutic intervention.

MDM2 is an E3 ubiquitin-protein ligase that engages the transactivation domain of p53 by a helix-in-groove
interaction.7 Whereas the MDM2-p53 interaction results in p53 ubiquitination and degradation, an analogous
helix-in-groove interaction between MDMX and p53 thwarts transcriptional activity by complex formation.
Although MDMX does not possess E3 ligase activity, it enhances MDM2-mediated degradation of p53.8
Importantly, both MDM2 and MDMX are essential to negative regulation and homeostasis of p53 at the
organism level, as evidenced by the embryonic lethality of MDM2 or MDMX deletion in mice.9,10 In human
cancer, the finding of suppression of p53 by overexpression of MDM2, whether by gene amplification or
protein upregulation, inspired the development of small molecule MDM2 inhibitors to restore the p53 tumor
suppressor pathway.11 However, sequestration of drug-induced p53 by MDMX was found to be a mechanism
of resistance to selective MDM2 inhibition.12 While MDM2 inhibitors have now advanced to clinical
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trials,13-15 clinically viable small molecules that target the corresponding groove on MDMX remain elusive.
Given the hematopoietic toxicity–especially thrombocytopenia–observed upon selective MDM2 inhibition in
the clinic16 and the role of MDMX in p53 suppression and in resistance to MDM2 inhibitor treatment, the
development of dual MDM2- and MDMX-directed agents offers a path to more complete inhibition of
negative p53 regulation. Yet, such agents have not been clinically tested.

Here, we report the results of the first phase 1 trial of ALRN-6924, a stabilized, cell-permeating α-helical
peptide that mimics the transactivation domain α-helix of p53 to bind with high affinity to both MDMX and
MDM2. ALRN-6924 represents a new class of inhibitors of intracellular protein-protein interactions,
referred to as stapled peptides, that contain a bridging hydrocarbon linker to maintain the α-helical shape of
bioactive peptides and simultaneously confer proteolytic resistance and cell permeability.17-19 While early
stapled peptide prototypes showed inconsistent results in vitro under standard serum-containing tissue
culture conditions,20 detailed optimization of p53 stapled peptides to improve their biological and
biophysical properties led to the development of ALRN-6924, which consistently demonstrated onmechanism activity in vitro under standard serum-containing tissue culture conditions as well as anti-tumor
activity in mouse models of TP53 wild-type hematologic malignancies and solid tumors, providing proof-ofconcept for clinical translation.21-23 To evaluate the safety and preliminary activity of ALRN-6924 in human
cancer, we conducted a phase 1 dose escalation study of 71 patients with advanced solid tumors or
lymphomas. Now, we report the tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of
this first-in-class representative of the novel stapled peptide therapeutic modality.
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Methods
Patient Selection
Patients 18 years or older with advanced solid tumors or lymphomas were recruited to participate in this
phase I, open-label, multicenter, dose escalation trial at eight centers throughout the United States. Patients
with solid tumors were required to have at least one target lesion per Response Evaluation Criteria in Solid
Tumors (RECIST) 1.1, and patients with lymphomas were required to have at least one measurable lesion
per Revised International Working Group Response Criteria (IWG) 2014, following the exhaustion of
standard-of-care treatment options. Eligibility criteria also included Eastern Cooperative Oncology Group
performance status of 0-1; life expectancy ≥3 months; and adequate hematologic, hepatic, coagulation, and
renal function (see protocol in Supplemental Information for detailed eligibility criteria). Women with
childbearing potential were required to have a negative serum or urine pregnancy test during screening. The
shorter of 4 weeks or 5 half-lives was required for the washout of all prior therapeutic agents unless no drugdrug interaction was anticipated and the patient had unequivocally experienced disease progression during
the most recent line of therapy.

Mandatory tumor TP53 mutation status evaluation was conducted in fresh or archival (≤1 year old) tumor
specimens using next-generation sequencing. However, for the three lowest dose levels of arm A, patients
were enrolled irrespective of TP53 mutation status. At higher dose levels, patients were required to have
wild-type TP53 based on either central or local laboratory assessment. Patients known to be human
papillomavirus positive were also excluded from enrollment because viral E6 protein can mediate p53
degradation. Patients without archived tissue and for whom a biopsy posed a significant risk were not
enrolled.
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Based on low central nervous system penetration of ALRN-6924 prototypes observed in preclinical studies,
patients with primary central nervous system tumors and patients with known brain metastasis were excluded
unless these metastases had been treated and been clinically stable for at least 30 days. Patients with
cardiovascular risk factors including the New York Heart Association class III or IV heart failure,
uncontrolled arrythmias or hypertension, and acute coronary syndromes within 6 months, as well as patients
with active or uncontrolled infections, including HIV/AIDS and hepatitis B and C, were excluded. Any
previous primary malignancy must have been in remission for at least 2 years, except for non-melanoma skin
cancers, carcinomas in situ, or squamous intraepithelial neoplasms. Patients with pulmonary embolism, deep
venous thrombosis, gastrointestinal hemorrhage in the past 6 months, hereditary angioedema of any severity,
or history of severe or life-threatening angioedema due to any cause were also excluded. Lastly, use of
concomitant medications that are predominantly cleared by organic anion transporter polypeptide (OATP)
hepatobiliary transporters OATP1B1 and OATP1B3 was prohibited within 48 hours of ALRN-6924 infusion
because ALRN-6924 is primarily cleared through hepatobiliary elimination and inhibits these transporters.

Before patient recruitment began at each participating site the protocol was approved by its institutional
review board. All patients provided written informed consent before undergoing study-related procedures,
including the molecular assessment of tumor specimens. This trial was conducted in accordance with current
United States FDA regulations, ICH Good Clinical Practice Guidelines, the principles of the Declaration of
Helsinki, and local ethical and legal requirements.. This trial is registered on ClinicalTrials.gov
(NCT02264613).
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Study Design and Treatment Plan
A standard 3+3 dose escalation design was employed to independently assess two single-agent dosing
regimens: patients in treatment arm A received ALRN-6924 by intravenous (IV) infusion on days 1, 8, and
15 of a 28-day cycle, while those in treatment arm B received ALRN-6924 on days 1, 4, 8, and 11 of a 21day cycle. Enrollment began with arm A, and arm B was introduced once the third dose level on arm A was
reached. Subsequently, patients were assigned to one of the two dosing regimens based on the availability of
enrollment slots. Doses were doubled until ≥1 of 3 patients in a cohort experienced any grade ≥2 treatmentemergent adverse event (TEAE) that was possibly related to the study drug, at which time a modified
Fibonacci sequence was implemented.24 Intra-patient dose escalation was allowed.

The primary endpoints of the study were TEAEs, dose-limiting toxicities (DLTs), and safety assessments.
Secondary endpoints included overall response rate, time to response, duration of response, disease control
rate, and duration of clinical benefit. Pharmacologic secondary endpoints included pharmacokinetic
parameters of ALRN-6924 and its primary metabolite; serum levels of macrophage inhibitory cytokine-1
(MIC-1), an established secreted biomarker of p53 activation; and immunogenicity as measured by anti-drug
antibody levels in blood.

Treatment continued until unacceptable toxicity, disease progression, or patient or physician decision to end
treatment. Patients experiencing clinical benefit could continue the study despite radiographic disease
progression.
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Toxicity Assessments
Adverse events were recorded at each visit and graded by National Cancer Institute Common Terminology
Criteria for Adverse Events, version 4.03. DLTs were defined as any grade ≥3 non-hematologic adverse
event, excluding the following: fatigue, nausea, emesis, diarrhea, or mucositis that responded to supportive
treatment within 48 hours; electrolyte aberrations that responded to correction within 24 hours; and grade ≤3
infusion-related reactions that did not require hospitalization. Hematologic DLTs included grade 4
thrombocytopenia of any duration; grade 3 thrombocytopenia lasting ≥7 days or associated with clinically
significant bleeding; grade 4 neutropenia lasting for ≥3 days; or any grade ≥3 febrile neutropenia.

Pharmacokinetics and Pharmacodynamics
The pharmacokinetic profiles of ALRN-6924 and its active metabolite ALRN-8714 in patient plasma were
assessed using a validated liquid chromatography method with tandem mass spectrometric detection. Blood
samples were obtained within 1 hour before the start and at the end of infusion (±5 minutes) and at 0.5, 1, 2,
4, 8, 24, and 48 hours after infusion on cycle 1 day 1 in both arm A and arm B. In addition, selective
sampling was done on subsequent dosing days in subsequent cycles of therapy in both regimens to evaluate
accumulation of exposure, dose-to-dose variability, and changes in exposure due to possible induction or
inhibition of clearance mechanisms. Pharmacokinetic parameters were calculated by non-compartmental
analysis using Phoenix WinNonlin v.8.1 and included maximum plasma concentration (Cmax), area under the
plasma concentration curve (AUC), and half-life calculations.

The pharmacodynamic profile of MIC-1 was assessed in patient serum samples using a validated,
quantitative sandwich enzyme-linked immunosorbent assay. Blood samples for serum MIC-1 levels were
obtained in parallel with plasma pharmacokinetic samples at the collection times noted above.
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Exploratory analyses included correlation of anti-tumor activity with baseline protein and gene expression
levels of p53, MDM2, MDMX, and related biomarkers in tumor biopsy tissue. Fresh or archival (≤1 year
old) formalin-fixed tumor specimens collected for next-generation sequencing of TP53 were further used for
immunohistochemistry analysis of protein biomarkers, and nucleic acid extracts for next-generation
sequencing were further used for qRT-PCR analysis of gene expression levels (Supplementary Methods and
Supplementary Table S1).

Response Assessment
Tumor response was assessed every 2 cycles (8 weeks) for patients in arm A and every 3 cycles (9 weeks)
for patients in arm B. Response was determined by the investigators in accordance with RECIST 1.1 for
patients with solid tumors25 and IWG 2014 for lymphoma patients.26 Patients were considered eligible for
response assessment if they had received at least one dose of ALRN-6924 and had undergone post-baseline
radiological tumor assessment or exhibited clinical or objective progression as determined by the investigator
and excluded patients with TP53-mutant tumors and patients in the lowest dose levels (<0.8 mg/kg). Data
cutoff date for the response analysis was 10 May 2020.

Drug Supply and Administration
ALRN-6924 was supplied and stored in single-use glass vials as a refrigerated (2° to 8° C) liquid product
dissolved at 15 mg/mL in 20 mM sodium phosphate, 240 mM trehalose, and 300 ppm polysorbate 20, pH
7.5. A weight-adjusted dose of the ALRN-6924 drug product was diluted into 250 mL, 5% dextrose in water
for IV administration to patients via a 1-hour infusion, except for dose level 7-2 in arm A, which was infused
over 2 hours.
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Results
Patient Characteristics
From October 2014 to January 2017, 71 patients were enrolled, with 41 (58%) allocated to treatment arm A
and 30 (42%) allocated to treatment arm B. At the time of data cutoff for analysis (13 April 2018), 66
(93.0%) of 71 patients had discontinued study treatment: 38 in treatment arm A and 28 in arm B. Key
demographics and baseline characteristics are shown in Table 1 and were similar for those in treatment arms
A and B. Overall, the median age was 61.0 years, and the percentages of men and women were similar
(49.3% and 50.7%, respectively), and most patients were Caucasian (74.6%). The patient population was
heavily pretreated, with 67.6% of patients having received more than two prior lines of systemic therapy,
including 43.7% of patients with at least five lines of prior therapy. Though not an exclusion factor, no
patients had prior therapy with an investigational MDM2 inhibitor. Of the 71 patients enrolled, 67 had solid
tumors, and four patients had lymphomas. Patients in the study had 24 different tumor types; these included
thymoma (n=5), peripheral T-cell lymphoma (PTCL; n=1), colorectal cancer (CRC; n=1), sarcoma (n=17),
Merkel cell carcinoma (n=4), renal cell carcinoma (n=2), ovarian cancer (n=2), adenoid cystic carcinoma
(n=5), hepatocellular carcinoma (n=1), melanoma (n=6), salivary gland cancer (n=3), breast cancer (n=3),
and other cancers (n=21). Patients were enrolled irrespective of TP53 status in the three lowest dose levels
(n=12) of arm A, which preceded enrollment in arm B; therefore, the TP53-wild-type (WT) confirmation rate
was higher for patients enrolled in arm B (100%) than in arm A (82.9%), or 90.1% (64/71) overall. Other
patients had either mutant (n=2) or indeterminate (n=5) TP53 status.

Patients were enrolled based on either central or local laboratory TP53 assessment. Twenty-nine patients
underwent both local and central laboratory testing, and five of these 29 patients (17.2%) had discrepant
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results (all TP53-WT on local testing and TP53-mutant on central testing), possibly due to differences in
gene coverage between local and central laboratory assays and instances in which different biopsy samples
(from primary tumor or metastases) were analyzed by the central and local laboratories. Details are provided
in Supplementary Table S2. These patients who were TP53-WT on local testing but TP53-mutant on central
laboratory assessment were excluded from the response-evaluable cohort.
Dose Escalation and Toxicity
As shown in Figure 1, arm A began enrollment at 0.16 mg/kg, and arm B began enrollment once the third
dose level in arm A (DL-3A) was completed. Enrollment proceeded in dose increments of 100% until grade
≥2 drug-related TEAEs were observed in DL-4A (fatigue) and in DL-3B (neutropenia); subsequent dose
escalations in DL-5A and DL-4B continued with a modified Fibonacci sequence (i.e., 67%, 50%, 40%, and
33%) up to 4.4 mg/kg once-weekly in arm A and 2.7 mg/kg twice-weekly in arm B. Due to hypotension
observed in patients during infusion at DL-7A, DL-7A-2 was introduced to evaluate a 2-hour infusion time
with dexamethasone and fluids administered in cycles 1 and 2. All other patients received ALRN-6924 via a
1-hour infusion.

All 71 enrolled patients received at least one dose of ALRN-6924 and were included in the safety analysis
population. All 71 patients experienced at least one TEAE. Common TEAEs (defined as ≥10% occurrences)
across both treatment arms are shown in Supplementary Table S3. These TEAEs were primarily grade 1 and
2 (60.6%), and the most frequent TEAEs regardless of relationship to study treatment included nausea
(73.2%), fatigue (60.6%), vomiting (46.5%), anemia and headache (31.0% each), decreased appetite and
constipation (29.6% each), and diarrhea (19.7%). In general, there were no marked differences in the
incidence of TEAEs between arm A and arm B and no apparent dose-related trends. There were no fatal
TEAEs.
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Table 2 shows all observed grade ≥3 drug-related TEAEs. Overall, these occurred in 22.5% of patients
(16/71). The rate of drug-related grade ≥3 TEAEs was similar in arms A and B. Only two patients
experienced drug-related grade 4 TEAEs, one patient with neutropenia in each arm; no grade 5 TEAEs were
observed.

Protocol-defined DLTs were experienced by five patients in treatment arm A. Dose escalation for this
regimen proceeded to the 3.1 mg/kg dose level, wherein nine patients were treated and only one experienced
a DLT (i.e., grade 3 fatigue that did not respond to supportive treatment within 48 hours). Dose escalation
then continued to 4.4 mg/kg, where four DLTs were noted among the 11 patients across both 1- and 2-hour
ALRN-6924 infusions, including grade 3 anemia (n = 1), grade 3 hypotension (n = 1), grade 4 neutropenia (n
= 1), and grade 3 elevated alkaline phosphatase level (n = 1). The patient with a DLT of grade 3 fatigue
recovered following dose delay within the seven days prior to the next clinical visit and continued treatment
after dose reduction. The patient with grade 3 anemia continued treatment without dose reduction and
without clinical symptoms or complications and recovered within 34 days. The patients experiencing DLTs
of grade 3 hypotension and grade 4 neutropenia discontinued treatment and recovered within 5 and 7 days,
respectively. The patient with a DLT of grade 3 elevated alkaline phosphatase level discontinued treatment
and did not recover, and a subsequent liver biopsy revealed diffuse breast cancer metastases. Based on these
DLTs, ALRN-6924 administered at 4.4 mg/kg once-weekly in arm A was considered to exceed the
maximum tolerated dose (MTD) and was not further explored. The safety, PK, PD, and anti-tumor activity
of ALRN-6924 at doses up to 3.1 mg/kg was considered favorable for further exploration as a single-agent in
specific tumor types and in combination studies with other anti-cancer agents. While no DLTs were observed
in arm B, and the efficacy profile in arm B was similar to that in arm A (vide infra), the twice-weekly
regimen was considered less convenient than the once-weekly schedule and was not pursued.
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A total of 11 serious adverse events (SAEs) were reported in seven patients in arm A and one patient in arm
B. Of these serious adverse events, three in two patients were considered treatment-related. One patient had
grade 3 hypotension and shortness of breath at the 3.1 mg/kg dose level in arm A, likely due to a drug-drug
interaction. This patient presented with hypotension the day after ALRN-6924 dosing following selfadministration of the anti-hypertensive agent telmisartan, a prohibited concomitant medication. Telmisartan
is primarily cleared by hepatobiliary transporter OATP1B3, for which ALRN-6924 is an inhibitor.27
Pharmacokinetic samples from this patient showed elevated plasma levels of telmisartan from the selfadministered dose. The second patient had two events of grade 3 hypotension at the 4.4 mg/kg dose level in
arm A, a dose level determined to be above the MTD. Both events occurred at the time of infusion and no
apparent drug-drug interaction was identified. The second event resulted in discontinuation of study
treatment and was considered a DLT as discussed above. To mitigate potential infusion-related hypotension
as a safety concern, the clinical protocol was amended to specify that IV fluids (saline) or oral fluids (500mL
– 1000 mL) should be administered at the end of the infusion.

Five patients (7.0%) discontinued treatment due to at least one drug-related TEAE, all in arm A. The TEAEs
leading to treatment discontinuation were infusion-related reactions (n = 3), hypotension (n = 1), and
neutropenia (n = 1).

The rates of dose reductions were 6/41 (14.6%) in arm A and 3/30 (10%) in arm B. In arm A, the dose of
ALRN-6924 was reduced in response to mild to moderate fatigue, nausea, and vomiting in five patients
across dose levels from 2.1 to 4.4 mg/kg, and in one patient with grade 2 chest pain at 2.1 mg/kg. In arm B,
one patient with grade 3 diarrhea at the 0.8 mg/kg dose level was dose-reduced, as was one patient with

18

Downloaded from clincancerres.aacrjournals.org on September 6, 2021. © 2021 American Association for Cancer
Research.

Author Manuscript Published OnlineFirst on July 22, 2021; DOI: 10.1158/1078-0432.CCR-21-0715
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

grade 3 nausea at 2.0 mg/kg and one patient with grade 1 fatigue and grade 1 nausea at 2.7 mg/kg. Notably,
the observed toxicities were acute, with no evidence of cumulative hematologic or non-hematologic
toxicities. Ophthalmic examination was not specified in the ALRN-6924 clinical trial, and no serious AEs
related to eye disorders were reported.

Pharmacokinetic and Pharmacodynamic Studies
Noncompartmental pharmacokinetic parameters and fold-change from baseline in serum MIC-1 levels are
shown in Table 3. Following a single IV infusion, ALRN-6924 achieved Cmax at the end of infusion, and the
mean Cmax values ranged dose-proportionally from 3.4 to 96.4 µg/mL over the dose range of 0.16 to 4.4
mg/kg (Figure 2A). The mean AUC across all collection time points (AUCall) increased slightly more than
dose-proportionally from 8.0 to 1200 µg.hr/mL over this same dose range, while the mean half-life also
increased with increasing dose levels and ranged from 1.5 to 6.8 h (see Supplemental Information). The
mean apparent clearance decreased with increasing dose and ranged from 3.70 to 23.5 mL/h/kg, whereas
volume of distribution ranged from 25.7 to 51.1 mL/kg independent of dose level. Plasma pharmacokinetic
results for individual patients on subsequent dosing days and subsequent cycles of therapy showed no
accumulation of exposure, reproducible dose-to-dose exposure, and no indication of changes in exposure due
to possible induction or inhibition of clearance mechanisms (data not shown). Noncompartmental
pharmacokinetic parameters for seven patients with complete pharmacokinetic sample collection at the 3.1
mg/kg dose level are shown in Figure 2B. At the RP2D, ALRN-6924 exhibited a Cmax of 71.2 µg/mL, AUCall
of 705 µg.hr/mL, and half-life of 5.4 hours, with a coefficient of variation of 20% and 26% for Cmax and
AUCall, respectively. No ALRN-6924-specific anti-drug antibodies were detected in any patient following
administration of ALRN-6924.
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Pharmacodynamic activity of ALRN-6924 was demonstrated by dose-related elevations of serum MIC-1,
which is an established biomarker for activation of the p53 pathway (Figure 2C). A 10-fold increase in MIC1 levels was observed by 8 hours after a single dose starting at 0.8 mg/kg, with a gradual decline to baseline
after 24 hours at doses of 1.25 mg/kg and below, while doses of 2.1 mg/kg and above demonstrated a
sustained elevation of MIC-1 up to 48 hours post-dose.

Anti-tumor Activity
The efficacy-evaluable population included patients who received at least one dose of ALRN-6924 at dose
levels ≥0.8 mg/kg, had confirmed TP53 wild-type tumors, and had undergone post-baseline radiological
tumor assessment or exhibited clinical or objective progression as determined by the investigator. A total of
41 of the 71 enrolled patients were evaluable for response (a CONSORT diagram is shown in Supplementary
Figure S1). The best change in target lesion size is shown in Figure 3A. Of the 41 evaluable patients, 24
patients (59%) demonstrated disease control by RECIST 1.1 or IWG 2014 criteria. Four patients achieved a
response: two patients (one with PTCL and one with Merkel cell carcinoma) achieved a confirmed complete
response (CR) and two patients (one with CRC and one with liposarcoma) demonstrated a confirmed partial
response (PR). Twenty patients (49%) achieved stable disease (SD), with 55% of the patients with SD
experiencing shrinkage of target lesions. The overall disease control rate was 59% (24/41), and among the 24
patients with disease control, the median duration of clinical benefit was 7.5 months at the time of data
cutoff. A swimmer plot of treatment duration is shown in Figure 3B.

Overall, seven of 71 patients received ≥15 cycles of treatment, and six patients remained on treatment for
over 1 year, including five patients who continued treatment beyond the data cutoff. A patient with PTCL
achieved a durable CR at cycle 6 of the 2.1 mg/kg dose level in arm A, and at the time of data cutoff, the
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patient had remained on treatment for 52 months. The patient with Merkel cell carcinoma showed a CR at
the sixth cycle of treatment at the 2.7 mg/kg dose level in arm B, and the CR lasted for 6.5 months; this
patient continued to receive clinical benefit and remained on treatment for 26 months. A patient with CRC
who was treated at the 0.8 mg/kg dose level in arm B experienced continuous tumor shrinkage that met the
criteria for PR at cycle 15 and remained on treatment for 16 months. A patient with liposarcoma achieved a
durable PR at the 4.4 mg/kg dose level in arm A at cycle 8 and remained on treatment for 32 months. Two
patients with thymoma achieved durable stable disease, one at the 2.1 mg/kg dose level in arm A for 57
months and another at the 2.7 mg/kg dose level in arm B for 17 months.

Association Between Molecular Alterations and Anti-tumor Activity
Genomic sequencing results from the Ion Torrent PGM platform (Knight Diagnostic Laboratories) were
available for all four patients with objective responses. The patient with rectal cancer who experienced a PR
had a KRAS G12D mutation and a subclonal PIK3CA P381S variant. The patient with Merkel cell cancer
who had a CR had a variant of unknown significance in ALK (N1394H). The other two patients, one with
liposarcoma and the other with PTCL, had no mutations in the 36 cancer-related genes sequenced.

We enrolled 10 TP53-WT patients with MDM2 amplification as determined by central or local laboratory
next-generation sequencing; of these, seven were in the efficacy-evaluable population (dose ≥0.8 mg/kg),
including four patients with liposarcoma and one patient each with bladder carcinoma, gastric
adenocarcinoma, and breast cancer. Among these seven MDM2-amplified, efficacy-evaluable patients, five
patients (71%) patients achieved disease control, including one with PR (liposarcoma) and four with SD as
best overall response (Figure 3A).
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Anti-tumor activity was compared to pretreatment tumor biopsy levels of the full-length MDMX gene
transcript (MDMX-FL) and a splice variant that skips exon 6 to encode a truncated isoform, MDMX-short.
Nucleic acid extracts derived from tumor tissue for next-generation sequencing of TP53 were available in
sufficient quantity for gene expression analysis for 28 of 41 efficacy-evaluable patients, including all four
patients with CR or PR, and 13 with SD as their best response, and 11 with PD as their best response. As
shown in Figure 2C, across the range of tumor types evaluated in this phase 1 study, a trend was observed in
which patients with lower expression levels of MDMX-short were more likely to achieve disease control (CR,
PR, or SD as best overall response) than were patients with higher MDMX-short levels; however, this
association did not reach statistical significance.

Additional biomarker analyses showed no trend between ALRN-6924 anti-tumor activity and protein levels
of p53, MDM2, or MDMX-FL by either immunohistochemistry analysis of available formalin-fixed
pretreatment biopsy samples or by gene expression levels of TP53, MDM2, or MDMX-FL (data not shown).
MDMX-short protein levels were not evaluated by immunohistochemistry.

Discussion
This study is the first clinical trial of ALRN-6924, a stabilized, cell-permeating, α-helical stapled peptide,
and is also the first clinical trial of a dual MDM2/MDMX inhibitor. Two single-agent dosing regimens were
evaluated to assess safety and anti-tumor activity on a once-weekly or twice-weekly dosing schedule, with
these treatment regimens including a 14-day (arm A) or 10-day (arm B) break between the last dose of one
cycle and the first dose of the next, to allow recovery from potential toxicities. ALRN-6924 showed a good
safety profile, with mild to moderate nausea, fatigue, and vomiting as the most common drug-related
toxicities, and yielded disease control and objective responses in patients with a variety of tumor types.
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Over the past decade, several MDM2 inhibitors have entered clinical trials, including RG7112 (RO5045337),
idasanutlin (RG7388), AMG-232 (KRT-232), APG-115, CGM097, siremadlin (HDM201), milademetan
(DS-3032b), MK-8242, and SAR405838.13,14,28-35 A striking finding in our study was the limited
myelosuppressive effect of ALRN-6924, in contrast with clinical trial reports from small molecule MDM2
inhibitors (Supplementary Table S4). In reports from other MDM2 inhibitors, neutropenia and
thrombocytopenia were often the dose limiting toxicities as detailed in a recent review by Konopleva et al.28
MDM2 is involved in normal hematopoiesis, and treatment with MDM2 antagonists can lead to on-target
hematopoietic defects.36,37 Of all 37 normal tissues reported in the Protein Atlas,38,39 MDMX expression is
highest in bone marrow cells, which may contribute to the lower degree of bone marrow toxicity observed
with a dual MDM2/MDMX inhibitor. We speculate that high MDMX levels may act as a pharmacokinetic
“sink” to sequester ALRN-6924 in bone marrow cells and minimize its inhibition of MDM2, thereby
minimizing MDM2-mediated ubiquitination and degradation of p53 in bone marrow cells. This concept
remains a topic of continued research.40

ALRN-6924 demonstrated favorable pharmacokinetic properties, with reproducible patient-to-patient values
for key pharmacokinetic parameters as judged by the narrow coefficients of variation for Cmax and AUCall,
20%, and 26%, respectively. This narrow range of variability in exposure contrasts with the inherent
variability associated with uptake of oral drugs, allowing target therapeutic exposures to be more readily
achieved with IV administration of ALRN-6924 without unexpected high exposure leading to toxicities seen
with oral agents, in particular small molecule MDM2 inhibitors, which are oral.
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Because ALRN-6924 activates p53, which is a transcription factor, the pharmacodynamic response to
ALRN-6924 is moderated by the unique nature of its target. Serum levels of MIC-1, a protein under
transcriptional control of p53, rapidly increased after ALRN-6924 dosing, demonstrating activation of the
p53 pathway in tissues in response to the drug. MIC-1 levels were sustained for over 48 hours at the RP2D,
well after the drug was mostly cleared from circulation, indicating a long-acting PD effect of p53 activation
by ALRN-6924. This multi-day PD effect, considered in tandem with the disease control rate and objective
responses observed on both once-weekly and twice-weekly dosing regimens, indicates that intermittent IV
dosing of ALRN-6924 can produce satisfactory anti-tumor activity, and more frequent administration is not
necessarily needed despite a plasma half-life of 5.4 hours at the RP2D.

The once-weekly dosing of ALRN-6924 at 3.1 mg/kg was chosen as the RP2D based on observed safety,
tolerability, and anti-tumor activity. No DLTs were observed in arm B, and while the per-cycle drug
exposure and favorable risk/benefit profile were similar for the two regimens at the highest tolerated doses
tested, the once-weekly infusion schedule was considered more convenient by patients and investigators.

Encouraging single-agent activity, including durable CRs and PRs, was observed in a number of patients
with different tumor types despite the heavily pretreated nature of this patient population. Furthermore, more
than half of the evaluable patients achieved disease control. The durable CRs seen in Merkel cell carcinoma
and PTCL highlight these diseases as potential therapeutic opportunities. The PR observed in the patient with
colorectal cancer harboring KRAS mutation emphasizes that although TP53 mutations are known to be
enriched in metastatic CRC compared to primary tumors, over 40% of patients with CRC have TP53-WT
tumors, so targeting MDM2/MDMX may hold promise.41,42 Notably, a previous study with SAR405838 and
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pimasertib also showed some activity, with prolonged SD in CRC patients with a KRAS mutation and TP53WT.43

Liposarcoma has been considered a disease of interest for MDM2 inhibitors, as MDM2 amplifications have
been reported in over 60% of liposarcomas.44 Further, in dedifferentiated liposarcoma, MDM2 amplification
and MDM2 overexpression was associated with shorter time to recurrence after surgical resection and
reduced overall survival in patients receiving systemic therapy.45 In the phase I trial reported here, we
observed a partial response in one of five evaluable patients with liposarcoma and stable disease in the other
four. Partial responses have also been reported in liposarcoma with other MDM2 inhibitors, including MK8242 and milademetan (DS-3032B or RAIN-32),29,30 emphasizing that targeting MDM2 or MDM2/MDMX
in liposarcoma alone or in combination therapy may be another therapeutic opportunity.

An intriguing correlation was observed between anti-tumor activity and pretreatment expression levels in
patient tumors for an MDMX splice variant that skips exon 6 to encode a truncated isoform, MDMX-short.
High expression of MDMX-short has been associated with faster progression and poorer survival in several
cancers.46 While the exact mechanism of this association remains controversial, one theory suggests that
alternate splicing is a mechanism for posttranslational regulation of MDMX-FL protein levels, such that the
MDMX-short splicing event leads to nonsense-mediated mRNA decay and a truncated protein that is also
rapidly degraded, yielding lower levels of MDMX-FL protein expression.47 Therefore, tumor cells with low
levels of MDMX-short expression may have higher MDMX-FL expression and greater dependence on MDMX
for p53-dependent and p53-independent mechanisms for survival.48 Analysis of the 28 efficacy-evaluable
patients for whom a sufficient sample was available revealed that across the range of tumor types and doses
evaluated in this phase 1 study, patients with lower expression levels of MDMX-short were more likely to
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achieve disease control (CR, PR, or SD as best overall response) than were patients with higher MDMX-short
levels. While the number of patients tested in this assay was small and the results did not reach statistical
significance, the trend suggests that MDMX inhibition by ALRN-6924 provides greater anti-tumor activity
against tumors with lower MDMX-short levels. Alternative MDMX splicing is one of several mechanisms that
can affect the function of p53, but with further study, this biomarker may be useful to select patients with a
higher likelihood of response to ALRN-6924 therapy.

The disease control rate observed in this study suggests that p53 activation by ALRN-6924 may induce cell
cycle arrest in TP53-WT tumor tissues, while the favorable tolerability profile, especially the virtual absence
of thrombocytopenia and neutropenia that is otherwise common for MDM2 inhibitors, indicates that ALRN6924 does not induce profound levels of apoptosis in healthy tissues such as bone marrow, even at the
highest tested doses. This further suggests that besides its use as an anti-cancer drug, ALRN-6924 may be an
ideal agent for treatment of normal, healthy TP53-WT tissues, such as bone marrow, when administered at
lower doses more likely to induce cell cycle arrest, resulting in protection from the toxic effects of
chemotherapy. This concept, known as cyclotherapy,49 has been proposed for MDM2 inhibitors50,51 and was
recently demonstrated in the clinic for a CDK4/6 inhibitor.52 Because approximately half of all cancers carry
inactivating mutations in the TP53 gene, which renders TP53-mutant cancer cells insensitive to the effects of
ALRN-6924, prophylactic treatment with ALRN-6924 prior to chemotherapy may induce cell cycle arrest in
normal tissues with wild-type TP53 while leaving the rapidly proliferating TP53-mutant cancer cells
susceptible to S- or M-phase poisons, such as topoisomerase inhibitors (which are most effective in S phase)
or drugs targeting the mitotic spindle, such as taxanes (which are most effective during mitosis).53
In conclusion, this study demonstrated the safety of first-in-class dual MDM2/MDMX inhibitor of ALRN6924. ALRN-6924 yielded disease control and objective responses in patients with a variety of TP53-WT
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tumors. The limited myelosuppression observed has provided rationale for ongoing clinical trials with
ALRN-6924 as a chemoprotective drug for patients with TP53-mutant cancers.
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Table 1: Demographic characteristics of patients overall and in treatment arms A and B.
Characteristics
Arm A (n=41) Arm B (n=30) Total (n=71)
Median age, years (range)
62 (25-78)
58 (31-76)
61 (25-78)
Sex, n (%)
Male
20 (48.8)
15 (50.0)
35 (49.3)
Female
21 (51.2)
15 (50.0)
36 (50.7)
Race, n (%)
Caucasian
28 (68.3)
25 (83.3)
53 (74.6)
African American
9 (22.0)
4 (13.3)
13 (18.3)
Asian
1 (2.4)
0
1 (1.4)
Other
3 (7.3)
1 (3.3)
4 (5.6)
Ethnicity, n (%)
Hispanic or Latino
4 (9.8)
1 (3.3)
5 (7.0)
Not Hispanic or Latino
34 (82.9)
26 (86.7)
60 (84.5)
Unknown
3 (7.3)
3 (10)
6 (8.5)
ECOG PS, n (%)
0
13 (31.7)
9 (30.0)
22 (31.0)
1
28 (68.3)
21 (70.0)
49 (69.0)
Prior lines of treatment, n (%)
1 or 2
9 (22.0)
14 (46.7)
23 (32.4)
3 or 4
11 (26.8)
6 (20.0)
17 (23.9)
≥5
21 (51.2)
10 (33.3)
31 (43.7)
Tumor TP53-WT, n (%)
34 (82.9)
30 (100)
64 (90.1)
ECOG PS, Eastern Cooperative Oncology Group performance status
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Table 2: Drug-related grade ≥3 treatment-emergent adverse events
Arm A
n=41
n (%)
10 (24.4)

Patients with at least
one grade ≥3 TEAE
event
Adverse Event
Fatigue
2 (4.9)
Anemia
1 (2.4)
Neutropenia
1 (2.4)
Nausea
1 (2.4)
Infusion-related
2 (4.9)
reaction
Hyponatraemia
1 (2.4)
Hypotension
2 (4.9)
Diarrhea
0
Vomiting
0
Asthenia
1 (2.4)
Aspartate
1 (2.4)
aminotransferase
increased
Alkaline
1 (2.4)
phosphatase
increased
Hypoxia
1 (2.4)
TEAE, treatment-emergent adverse event.

Arm B
n=30
n (%)
6 (20.0)

Total
n=71
n (%)
16 (22.5)

1 (3.3)
1 (3.3)
1 (3.3)
1 (3.3)
0

3 (4.2)
2 (2.8)
2 (2.8)
2 (2.8)
2 (2.8)

1 (3.3)
0
1 (3.3)
1 (3.3)
0
0

2 (2.8)
2 (2.8)
1 (1.4)
1 (1.4)
1 (1.4)
1 (1.4)

0

1 (1.4)

0

1 (1.4)
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Table 3. Noncompartmental pharmacokinetic parameters and fold-change from baseline in
serum MIC-1 levels [mean (% CV)] for patients with complete sample collection following a
single one-hour IV infusion on cycle 1 day 1 at select doses.

N

0.16
mg/kg

0.32
mg/kg

0.53
mg/kg

0.64
mg/kg

1.25
mg/kg

2.1
mg/kg

3.1
mg/kg

4.4
mg/kg

5

3

5

4

2

6

7

8

AUCall
8.02
17.8
42.8
55.6
164
434
705
1200
(µg*h/mL) (52.7)
(20.4)
(68.9)
(25.3)
(35.2)
(53.2)
(26.4)
(14.5)
Cmax
3.37
5.56
10.1
13.4
27.7
45.2
71.2
96.4
(µg/mL)
(26.5)
(5.8)
(40.8)
(16.6)
(22.5)
(40.4)
(19.6)
(13.1)
t1/2
1.5
1.97
2.57
2.72
2.22
4.63
5.36
6.84
(h)
(64.4)
(54.1)
(49.7)
(52.9)
(6.9)
(40.5)
(38.6)
(25.6)
CL
23.5
17.4
16.6
12.1
8.10
6.49
4.74
3.70
(mL/h/kg) (43.1)
(30.7)
(56.3)
(25.5)
(35.1)
(63.1)
(40.5)
(15.4)
Vz
42.2
44.3
50.8
51.1
25.7
41.8
33.8
36.8
(mL/kg)
(46.6)
(31.2)
(40.7)
(76.9)
(28.5)
(62.8)
(26.9)
(36.4)
MIC-1
7.7
6.0
8.9
10.5
9.6
9.6
n/d
n/d
at 8 hr
(100)
(28)
(14)
(77)
(73)
(39)
MIC-1
2.9
1.7
3.1
4.8
16.3
21.6
19.9
26.3
at 24 hr
(102)
(40)
(42)
(75)
(32)
(87)
(67)
(57)
MIC-1
1.4
1.1
1.5
1.6
2.6
8.1
14.0
24.2
at 48 hr
(51)
(12)
(38)
(35)
(31)
(91)
(79)
(59)
AUCall, area under the curve for all measurable sampling times; CL, clearance; Cmax, maximum
concentration; CV, coefficient of variation; hr, hour(s); N, number; n/d = not determined; t1/2,
half-life; Vz, volume of distribution
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Figure 1. Study schema. Patients in arm A received ALRN-6924 on days 1, 8, and 15 of
a 28-day cycle, while those in arm B received ALRN-6924 on days 1, 4, 8, and 11 of a
21-day cycle.
Figure 2. Pharmacokinetics and pharmacodynamics, and association of anti-tumor
activity with MDM2 amplification and MDMX-short splice variant expression. (A) Plasma
levels of ALRN-6924 following a single one-hour IV infusion. For clarity, only dose levels
in arm A are shown. (B)) Mean increase from baseline in serum macrophage inhibitory
cytokine 1 levels following a single dose of ALRN-6924. For clarity, only select dose
levels are shown. (C)Expression levels of the MDMX-short splice variant in pretreatment
tumor biopsy specimens for 28/41 efficacy-evaluable patients versus best overall
response. Line demarks median value. Two-tailed p value = 0.099 (n.s.).
Figure 3. (A) Best overall response for efficacy-evaluable patients treated with ALRN6924. The graph shows best response per the Response Evaluation Criteria in Solid
Tumors 1.1 (or Revised International Working Group Response Criteria 2014 for
patients with lymphoma) in 39 of 41 efficacy-evaluable patients. Two efficacy-evaluable
patients with non-radiological evidence of disease progression are not shown.
Response-evaluable patients with TP53-WT tumors with MDM2 amplification are
designated with an asterisk (*). (B) Swimmer plot of treatment duration for 41 efficacyevaluable patients in arms A and B
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